Dyslipidemia is an important factor in the causation of macrovascular disease in type 2 diabetics. The role of atorvastatin in the management of dyslipidemia in patients with type 2 diabetes mellitus is not very well elucidated. The American College of Cardiology and American Diabetes Association suggest the aggressive therapy of diabetic dyslipidemia will reduce the rik of coronary heart disease in diabetics and that optmal levels are serum low-density lipoprotein cholesterol 1.15 mmol/L (>45 mg/dl) and triglycerdes 45 mg/dl was not achieved, the dose of atorvastatin was increased to 20mg at bedtime for another 6 weeks. It was observed that low-density lipoprotein dyslipidemia was most prevalent. In the control group, a favourable alteration in lipid levels was brought about but none was statistically significant and the American Diabetes Association goals were not lipid moieties, and the target levels were achieved in 80% of patients after 12 weeks. There was no significant alteration in glycemic control and liver functions. Myopathy was not seen in any patient. In our study, behavioral modification alone did not achieve the larget levels of various lipids in diabetic dyslipidemia as per the American Diabetes Association guidelines. Hence, pharmacological therapy with statins should be resorted to in patients with type 2 diabetes mellitus who carry a high risk of coronary hearts disease. Atorvastatin is a safe and effective lipid-lowering drug.